ISPC - iSpecimen Inc.
NASDAQ
->
Healthcare
->
Diagnostics & Research
Lexington,
United States
Type: Equity
ISPC price evolution
ISPC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $1.75 | $2.15 | $2.09 | $2.34 |
| Short term investments | ||||
| Net receivables | $2.63 | $2.85 | $2.42 | $2.94 |
| Inventory | ||||
| Total current assets | $4.66 | $5.24 | $5.29 | $8.24 |
| Long term investments | ||||
| Property, plant & equipment | $0.44 | $0.13 | $0.27 | $0.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $11.26 | $11.9 | $12.51 | $15.82 |
| Current liabilities | ||||
| Accounts payable | $4.06 | $4.21 | $3.56 | $3.93 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $6.27 | $5.81 | $5.7 | $6.05 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $6.55 | $5.81 | $5.7 | $6.08 |
| Shareholders' equity | ||||
| Retained earnings | -$65.82 | -$64.38 | -$62.27 | -$59.36 |
| Other shareholder equity | $0 | $0 | ||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2.34 | $15.31 | $27.74 | $0.7 |
| Short term investments | ||||
| Net receivables | $2.94 | $4.07 | $4.88 | $2.36 |
| Inventory | ||||
| Total current assets | $8.24 | $19.68 | $32.95 | $3.47 |
| Long term investments | ||||
| Property, plant & equipment | $0.32 | $0.41 | $0.03 | $0.08 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $2.74 | |||
| Total investments | ||||
| Total assets | $15.82 | $24.62 | $35.72 | $6.21 |
| Current liabilities | ||||
| Accounts payable | $3.93 | $2.46 | $0.83 | $1.79 |
| Deferred revenue | $0.87 | |||
| Short long term debt | ||||
| Total current liabilities | $6.05 | $4.28 | $2.51 | $22.14 |
| Long term debt | $3.42 | $0.18 | ||
| Total noncurrent liabilities | $0.18 | |||
| Total debt | ||||
| Total liabilities | $6.08 | $4.31 | $5.93 | $22.31 |
| Shareholders' equity | ||||
| Retained earnings | -$59.36 | -$48.27 | -$38.02 | -$29.06 |
| Other shareholder equity | $0 | $11.17 | ||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.66 | $2.86 | $2.29 | $2.58 |
| Cost of revenue | ||||
| Gross Profit | $1.11 | $1.44 | $1.29 | $1.15 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $2.81 | $3.62 | $4.29 | $4.02 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | -$0.01 | $0 | $0.03 | $0.04 |
| Net income | ||||
| Net income | -$1.44 | -$2.11 | -$2.9 | -$3.07 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.93 | $10.4 | $11.14 | $8.18 |
| Cost of revenue | ||||
| Gross Profit | $5.11 | $5.65 | $5.89 | $4.6 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $16.28 | $15.45 | $11.81 | $7.59 |
| Operating income | -$2.41 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | $0.32 | -$0.07 | -$0.78 | $2.1 |
| Net income | ||||
| Net income | -$11.1 | -$10.25 | -$8.96 | -$4.65 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $2.05 | $2.23 | $1.94 | -$7.23 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $2.05 | $1.19 | -$0.12 | $0.07 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.59 | -$0.19 | -$0.25 | -$12.97 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | -$4.65 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.29 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$7.23 | -$3.19 | -$1.04 | -$1.1 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $0.07 | -$3.42 | $38.75 | $2.03 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$12.97 | -$12.43 | $27.04 | $0.64 |
News
Fundamentals
| Market cap | $529.43K |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 829.82K |
| Revenue | $10.39M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$9.52M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.06 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 0.05 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 2.11 |
| EPS | -$11.48 |
|---|---|
| ROA | -73.97% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.74 |
| Quick ratio | N/A |